These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37161050)

  • 21. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.
    Joller N; Hafler JP; Brynedal B; Kassam N; Spoerl S; Levin SD; Sharpe AH; Kuchroo VK
    J Immunol; 2011 Feb; 186(3):1338-42. PubMed ID: 21199897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 23. Gene of the month: T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT).
    Bolm L; Petruch N; Sivakumar S; Annels NE; Frampton AE
    J Clin Pathol; 2022 Apr; 75(4):217-221. PubMed ID: 35058314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
    Zhao J; Li L; Yin H; Feng X; Lu Q
    Int Immunopharmacol; 2023 Jul; 120():110358. PubMed ID: 37262959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity.
    Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ
    Front Immunol; 2023; 14():1280986. PubMed ID: 38022590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis.
    Li W; Deng C; Yang H; Lu X; Li S; Liu X; Chen F; Chen L; Shu X; Zhang L; Liu Q; Wang G; Peng Q
    Arthritis Res Ther; 2021 Jan; 23(1):15. PubMed ID: 33413573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy.
    Yamada T; Tatematsu M; Takasuga S; Fuchimukai A; Yamagata K; Seki S; Kuba K; Yoshida H; Taniuchi I; Bernhardt G; Shibuya K; Shibuya A; Yamada T; Ebihara T
    J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37036426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models.
    Zhao W; Dong Y; Wu C; Ma Y; Jin Y; Ji Y
    Exp Cell Res; 2016 Jan; 340(1):132-8. PubMed ID: 26683997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
    Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
    Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P2RX7 Deletion in T Cells Promotes Autoimmune Arthritis by Unleashing the Tfh Cell Response.
    Felix KM; Teng F; Bates NA; Ma H; Jaimez IA; Sleiman KC; Tran NL; Wu HJ
    Front Immunol; 2019; 10():411. PubMed ID: 30949163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Helios but not CD226, TIGIT and Foxp3 is a Potential Marker for CD4
    Yang M; Liu Y; Mo B; Xue Y; Ye C; Jiang Y; Bi X; Liu M; Wu Y; Wang J; Olsen N; Pan Y; Zheng SG
    Cell Physiol Biochem; 2019; 52(5):1178-1192. PubMed ID: 30990587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells.
    Yasutomi M; Christiaansen AF; Imai N; Martin-Orozco N; Forst CV; Chen G; Ueno H
    Front Immunol; 2022; 13():840457. PubMed ID: 35273617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced expression of TIGIT but not neuropilin-1 in patients with type 2 diabetes mellitus.
    Hoseini-Aghdam M; Sheikh V; Eftekharian MM; Rezaeepoor M; Behzad M
    Immunol Lett; 2020 Sep; 225():1-8. PubMed ID: 32540486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sepsis-Induced Immunosuppression Is Marked by an Expansion of a Highly Suppressive Repertoire of FOXP3+ T-Regulatory Cells Expressing TIGIT.
    de Lima MHF; Hiroki CH; de Fátima Borges V; Cebinelli GCM; Santos J; Rosa MH; Silva CMS; Wanderley CWS; Gonçalves AV; Quirino GFS; Zamboni DS; Cunha TM; Filho JA; Cunha FQ
    J Infect Dis; 2022 Feb; 225(3):531-541. PubMed ID: 34379757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A2Ar-dependent PD-1+ and TIGIT+ Treg cells have distinct homing requirements to suppress autoimmune uveitis in mice.
    Peters K; McDonald T; Muhammad F; Walsh M; Drenen K; Montieth A; Stephen Foster C; Lee DJ
    Mucosal Immunol; 2023 Aug; 16(4):422-431. PubMed ID: 37164238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
    Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
    J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TIGIT
    Muhammad F; Wang D; McDonald T; Walsh M; Drenen K; Montieth A; Foster CS; Lee DJ
    J Autoimmun; 2020 Jul; 111():102441. PubMed ID: 32201225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).
    Yasuma K; Yasunaga J; Takemoto K; Sugata K; Mitobe Y; Takenouchi N; Nakagawa M; Suzuki Y; Matsuoka M
    PLoS Pathog; 2016 Jan; 12(1):e1005372. PubMed ID: 26735971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.